Trevi Therapeutics Inc (TRVI) - Total Liabilities
Based on the latest financial reports, Trevi Therapeutics Inc (TRVI) has total liabilities worth $7.48 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Trevi Therapeutics Inc to track the company's year-over-year net asset growth rate.
Trevi Therapeutics Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Trevi Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Trevi Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Trevi Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NBT Bancorp Inc
NASDAQ:NBTB
|
USA | $14.10 Billion |
|
Shandong Linglong Tyre Co Ltd
SHG:601966
|
China | CN¥24.46 Billion |
|
Vietnam Airlines JSC
VN:HVN
|
Vietnam | ₫65.34 Trillion |
|
Epoxy Base Electronic Material Corp Ltd
SHG:603002
|
China | CN¥2.59 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr631.81 Million |
|
SBT Ultrasonic Technology Co. Ltd. A
SHG:688392
|
China | CN¥497.85 Million |
|
Embotelladora Andina S.A
F:AKOB
|
Germany | €2.22 Trillion |
|
BRP Inc
TO:DOO
|
Canada | CA$5.71 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Trevi Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Trevi Therapeutics Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 24.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Trevi Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Trevi Therapeutics Inc (2016–2025)
The table below shows the annual total liabilities of Trevi Therapeutics Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $10.20 Million | -9.43% |
| 2024-12-31 | $11.26 Million | +64.18% |
| 2023-12-31 | $6.86 Million | -55.93% |
| 2022-12-31 | $15.56 Million | -27.31% |
| 2021-12-31 | $21.40 Million | +7.81% |
| 2020-12-31 | $19.85 Million | +263.80% |
| 2019-12-31 | $5.46 Million | +71.46% |
| 2018-12-31 | $3.18 Million | -57.29% |
| 2017-12-31 | $7.45 Million | -71.15% |
| 2016-12-31 | $25.82 Million | -- |
About Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction i… Read more